These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 1982833

  • 21. Influence of recombinant human erythropoietin treatment on cortisol responses to insulin-induced hypoglycemia in CAPD patients.
    Díez JJ, Iglesias P, Sastre J, Gómez-Pan A, Selgas R, Romero JR, Méndez J.
    Adv Perit Dial; 1993; 9():336-41. PubMed ID: 8105958
    [Abstract] [Full Text] [Related]

  • 22. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity.
    Bajo MA, Selgas R, Miranda B, Fernandez-Zamorano A, Borrego F, Romero JR, Caparros G, Riñon C, Sanchez Sicilia L.
    Adv Perit Dial; 1991; 7():296-300. PubMed ID: 1680450
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
    Litwin M, Boguszewska-Baczkowska A, Jelonek A.
    Pol Tyg Lek; 1991; 49(6-7):135-6. PubMed ID: 8090665
    [Abstract] [Full Text] [Related]

  • 25. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
    Guízar JM, Gutiérrez MJ, Sánchez G, Kornhauser C.
    Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
    [Abstract] [Full Text] [Related]

  • 26. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
    Sikole A, Spasovski G, Zafirov D, Polenakovic M.
    Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
    [Abstract] [Full Text] [Related]

  • 27. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K, Onoyama K, Iseki K, Fujimi S, Fujishima M.
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [Abstract] [Full Text] [Related]

  • 28. Growth hormone and cortisol secretion before and after erythropoietin therapy in CAPD patients.
    Diez JJ, Iglesias P, Sastre J, Gomez-Pan A, Mendez J, Bajo MA, Selgas R.
    Adv Perit Dial; 1994 Jun; 10():275-81. PubMed ID: 7999845
    [Abstract] [Full Text] [Related]

  • 29. [Maintenance therapy on the anemia in continuous ambulatory peritoneal dialysis (CAPD) patients using subcutaneous administration of recombinant human erythropoietin fortnightly--a multicenter trial].
    Kubota M, Kawaguchi Y, Nomoto Y, Tsuchida H, Nihei H, Kubo K, Omori Y, Babazono T, Ogura Y, Hara S.
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1081-90. PubMed ID: 8230819
    [Abstract] [Full Text] [Related]

  • 30. Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin.
    Bárány P, Pettersson E, Ahlberg M, Hultman E, Bergström J.
    Clin Nephrol; 1991 Jun; 35(6):270-9. PubMed ID: 1873941
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 34. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B, Grujić-Adanja G.
    Srp Arh Celok Lek; 1997 May; 125(5-6):163-7. PubMed ID: 9265238
    [Abstract] [Full Text] [Related]

  • 35. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R, Bloom E, Johnson R, Goldstein M.
    Adv Perit Dial; 1994 May; 10():135-8. PubMed ID: 7999811
    [Abstract] [Full Text] [Related]

  • 36. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B.
    Ren Fail; 2005 May; 27(4):367-72. PubMed ID: 16060121
    [Abstract] [Full Text] [Related]

  • 37. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Pais MJ, Gaspar A, Santana A, Bruges M, Simões J.
    Perit Dial Int; 1993 May; 13 Suppl 2():S541-3. PubMed ID: 8399660
    [Abstract] [Full Text] [Related]

  • 38. [Extrinsic coagulation pathway in peritoneally dialyzed patients treated with erythropoietin].
    Małyszko J, Małyszko JS, Suchowierska E, Pawlak K, Myśliwiec M.
    Przegl Lek; 2002 May; 59(3):139-41. PubMed ID: 12184025
    [Abstract] [Full Text] [Related]

  • 39. [Low doses of recombinant erythropoietin in the treatment of renal anemia in patients on chronic hemodialysis and ambulatory peritoneal dialysis].
    Lashutin SV, Nikolaev AIu, Ermolenko VM, Shutov EV, Bezruk VG, Ivashchenko MA.
    Ter Arkh; 1999 May; 71(6):61-3. PubMed ID: 10420460
    [Abstract] [Full Text] [Related]

  • 40. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C, Blumberg A.
    Schweiz Med Wochenschr; 1990 Feb 17; 120(7):217-20. PubMed ID: 2309110
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.